CRC
MCID: CLR023
MIFTS: 100

Colorectal Cancer (CRC)

Categories: Blood diseases, Cancer diseases, Gastrointestinal diseases, Genetic diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Colorectal Cancer

MalaCards integrated aliases for Colorectal Cancer:

Name: Colorectal Cancer 57 11 73 28 53 5 41 2 14 36 63 16 71 75
Colon Cancer 57 11 73 28 53 5 2 14
Colorectal Carcinoma 11 28 53 5 14 16 71
Colon Carcinoma 11 53 14 16 71
Colorectal Cancer, Susceptibility to 57 28 5
Carcinoma of Colon 11 28 5
Colorectal Cancer with Chromosomal Instability, Somatic 57 5
Colon Cancer, Susceptibility to 57 5
Colon Cancer, Somatic 57 12
Colorectal Neoplasms 43 71
Colonic Neoplasms 43 71
Crc 57 73
Cancer, Colorectal, Susceptibility to 38
Colon Cancer, Advanced, Somatic 57
Cancer, Colorectal, Somatic 38
Colorectal Cancer, Somatic 57
Malignant Tumor of Colon 71
Colorectal Carcinomas 14
Colorectal Neoplasm 16
Colorectal Cancers 14
Colonic Carcinoma 11
Colonic Neoplasm 16
Colon Cancers 14
Cancer, Colon 38

Characteristics:


Inheritance:

Somatic mutation 57

Classifications:



External Ids:

OMIM® 57 114500
ICD9CM 34 153
ICD10 31 C18 C18.9
UMLS 71 C0007102 C0009375 C0009402 more

Summaries for Colorectal Cancer

PubMed Health : 63 Colorectal cancer: Colorectal (bowel) cancer is one of the more common forms of cancer in many countries, including Germany. The name "colorectal cancer" is used to describe bowel cancer that starts in the colon (the large intestine) or the rectum. Cancer of the small intestine is very rare. Colorectal cancer almost always develops from growths called colorectal polyps that form in the lining of the colon. But by no means do all polyps become cancerous – and if a polyp does become cancerous, it takes many years. One way to prevent colorectal cancer is to have a colonoscopy, which also allows doctors to remove polyps. Having colorectal cancer can be a life-changing experience. What happens after the diagnosis has been made will depend on various factors, including the stage of the cancer. In early-stage colorectal cancer, the tumor just needs to be surgically removed. In advanced stages, additional treatments may be considered, such as chemotherapy or radiation therapy. In Germany, high-quality medical care is available for people who have cancer. There are also a number of sources of support, for instance to help cope with the disease emotionally and make it easier to go back to work.

MalaCards based summary: Colorectal Cancer, also known as colon cancer, is related to lynch syndrome and colonic benign neoplasm, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Colorectal Cancer is CTNNB1 (Catenin Beta 1), and among its related pathways/superpathways are Disease and ERK Signaling. The drugs Ketamine and Tramadol have been mentioned in the context of this disorder. Affiliated tissues include colon, rectum and liver, and related phenotypes are renal cell carcinoma and neoplasm of the stomach

MedlinePlus: 41 The colon and rectum are part of the large intestine. Colorectal cancer occurs when tumors form in the lining of the large intestine. It is common in both men and women. The risk of developing colorectal cancer rises after age 50. You're also more likely to get it if you have colorectal polyps, a family history of colorectal cancer, ulcerative colitis or Crohn's disease, eat a diet high in fat, or smoke. Symptoms of colorectal cancer include: Diarrhea or constipation A feeling that your bowel does not empty completely Blood (either bright red or very dark) in your stool Stools that are narrower than usual Frequent gas pains or cramps, or feeling full or bloated Weight loss with no known reason Fatigue Nausea or vomiting Because you may not have symptoms at first, it's important to have screening tests. Everyone over 45 should get screened. Tests include colonoscopy and tests for blood in the stool. Treatments for colorectal cancer include surgery, chemotherapy, radiation, or a combination. Surgery can usually cure it when it is found early. NIH: National Cancer Institute

CDC: 2 Colorectal cancer is cancer that occurs in the colon or rectum. Sometimes it is called colon cancer, for short. As the drawing shows, the colon is the large intestine or large bowel. The rectum is the passageway that connects the colon to the anus. Sometimes abnormal growths, called polyps, form in the colon or rectum. Over time, some polyps may turn into cancer. Screening tests can find polyps so they can be removed before turning into cancer. Screening also helps find colorectal cancer at an early stage, when treatment works best.

OMIM®: 57 Colorectal cancer is a heterogeneous disease that is common in both men and women. In addition to lifestyle and environmental risk factors, gene defects can contribute to an inherited predisposition to CRC. CRC is caused by changes in different molecular pathogenic pathways, such as chromosomal instability, CpG island methylator phenotype, and microsatellite instability. Chromosome instability is the most common alteration and is present in almost 85% of all cases (review by Schweiger et al., 2013). (114500) (Updated 08-Dec-2022)

UniProtKB/Swiss-Prot: 73 A complex disease characterized by malignant lesions arising from the inner wall of the large intestine (the colon) and the rectum. Genetic alterations are often associated with progression from premalignant lesion (adenoma) to invasive adenocarcinoma. Risk factors for cancer of the colon and rectum include colon polyps, long-standing ulcerative colitis, and genetic family history.

Disease Ontology 11 Colorectal cancer: A large intestine cancer that is located in the colon and/or located in the rectum.

Colorectal carcinoma: A colorectal cancer that arises from the colon or rectum and invades through the muscularis mucosa into the submucosa.

Colon carcinoma: A colon cancer that has material basis in abnormally proliferating cells derives from epithelial cells.

Colon cancer: A colorectal cancer that is located in the colon.

Wikipedia: 75 Colorectal cancer (CRC), also known as bowel cancer, colon cancer, or rectal cancer, is the development... more...

Related Diseases for Colorectal Cancer

Diseases in the Colorectal Cancer family:

Colorectal Cancer 1 Colorectal Cancer 2
Colorectal Cancer 3 Colorectal Cancer 5
Colorectal Cancer 6 Colorectal Cancer 7
Colorectal Cancer 8 Colorectal Cancer 9
Colorectal Cancer 10 Colorectal Cancer 11
Colorectal Cancer 12 Familial Colorectal Cancer
Familial Colorectal Cancer Type X

Diseases related to Colorectal Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2118)
# Related Disease Score Top Affiliating Genes
1 lynch syndrome 35.1 TP53 PIK3CA MLH3 CTNNB1 CHEK2 BRAF
2 colonic benign neoplasm 34.2 TP53 PIK3CA CTNNB1 CHEK2 BRAF AXIN2
3 adenoma 34.0 TP53 PIK3CA CTNNB1 BRAF AXIN2 APC
4 familial adenomatous polyposis 33.9 TP53 MCC CTNNB1 BRAF AXIN2 APC
5 adenocarcinoma 33.7 TP53 PIK3CA FGFR3 CTNNB1 BRAF BAX
6 endometrial cancer 33.7 TP53 PIK3CA NRAS MLH3 FGFR3 CTNNB1
7 gastric cancer 33.6 TP53 PIK3CA NRAS EP300 CTNNB1 CHEK2
8 breast cancer 33.6 TP53 PIK3CA NRAS FGFR3 EP300 CTNNB1
9 cowden syndrome 33.5 TP53 PIK3CA MLH3 FLCN CTNNB1 CHEK2
10 rectal benign neoplasm 33.5 TP53 PIK3CA CTNNB1
11 hepatocellular carcinoma 33.5 TP53 PIK3CA PDGFRL NRAS EP300 CTNNB1
12 colon adenocarcinoma 33.3 TP53 PIK3CA CTNNB1 BRAF BAX APC
13 diffuse gastric and lobular breast cancer syndrome 33.2 TP53 PIK3CA CTNNB1 CHEK2
14 colorectal adenocarcinoma 33.2 TP53 PIK3CA CTNNB1 AKT1
15 colitis 33.1 PIK3CA CTNNB1 CHEK2 BRAF AKT1
16 bap1 tumor predisposition syndrome 33.1 TP53 FLCN CHEK2 AXIN2 APC
17 inherited cancer-predisposing syndrome 33.1 TP53 FLCN CHEK2 AXIN2 APC
18 lung cancer susceptibility 3 33.0 TP53 PIK3CA NRAS FGFR3 CTNNB1 BRAF
19 colorectal adenoma 33.0 TP53 CTNNB1 APC
20 esophageal cancer 32.9 TP53 PIK3CA EP300 DCC CTNNB1 CHEK2
21 small intestine cancer 32.9 TP53 PIK3CA CTNNB1
22 pancreatic cancer 32.8 TP53 PIK3CA CTNNB1 CHEK2 BUB1 BRAF
23 brain cancer 32.7 TP53 PIK3CA NRAS CTNNB1 BRAF BAX
24 glioblastoma 32.7 TP53 PIK3CA NRAS EP300 CTNNB1 BRAF
25 rectum adenocarcinoma 32.7 TP53 PIK3CA NRAS CTNNB1 APC
26 squamous cell carcinoma 32.7 TP53 PIK3CA NRAS FGFR3 EP300 CTNNB1
27 mismatch repair cancer syndrome 32.6 TP53 PIK3CA MLH3 CTNNB1
28 bladder cancer 32.6 TP53 PIK3CA NRAS FGFR3 CTNNB1 BRAF
29 intestinal benign neoplasm 32.6 TP53 PIK3CA CTNNB1 AXIN2 APC AKT1
30 neuroblastoma 32.5 TP53 PIK3CA NRAS CTNNB1 BAX AXIN2
31 colon adenoma 32.5 TP53 PIK3CA CTNNB1 AXIN2 APC AKT1
32 gastrointestinal stromal tumor 32.5 TP53 PIK3CA NRAS FGFR3 CTNNB1 BRAF
33 mucinous adenocarcinoma 32.5 TP53 PIK3CA CTNNB1
34 cervical cancer 32.4 TP53 PIK3CA FGFR3 EP300 CTNNB1 BAX
35 leukemia, acute myeloid 32.4 TP53 PIK3CA NRAS EP300 CTNNB1 CHEK2
36 diffuse gastric cancer 32.4 TP53 PIK3CA CTNNB1 CHEK2
37 ataxia-telangiectasia 32.4 TP53 CHEK2 BRAF BAX AKT1
38 gastric adenocarcinoma 32.4 TP53 PIK3CA NRAS CTNNB1 BRAF APC
39 squamous cell carcinoma, head and neck 32.3 TP53 PIK3CA FGFR3 EP300 CTNNB1 BRAF
40 renal cell carcinoma, nonpapillary 32.3 TP53 PIK3CA NRAS FLCN CTNNB1 BRAF
41 lymphoma, non-hodgkin, familial 32.2 TP53 PIK3CA NRAS BRAF BAX APC
42 sarcoma 32.2 TP53 PIK3CA CTNNB1 CHEK2 BRAF
43 cholangiocarcinoma 32.2 TP53 PIK3CA CTNNB1 BRAF AKT1
44 cowden syndrome 1 32.1 TP53 PIK3CA FLCN CTNNB1 CHEK2 AKT1
45 leukemia, chronic lymphocytic 32.1 TP53 NRAS CTNNB1 BRAF BAX APC
46 head and neck cancer 32.1 TP53 PIK3CA CTNNB1 APC AKT1
47 hereditary breast ovarian cancer syndrome 32.1 TP53 PIK3CA MLH3 CHEK2 BUB1B
48 skin disease 32.0 TP53 PIK3CA NRAS FGFR3 CTNNB1 APC
49 skin carcinoma 32.0 TP53 NRAS CTNNB1 AKT1
50 li-fraumeni syndrome 32.0 TP53 PIK3CA CTNNB1 CHEK2 BAX

Comorbidity relations with Colorectal Cancer via Phenotypic Disease Network (PDN): (show all 21)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Ascending Colon Cancer
Cecal Benign Neoplasm Deficiency Anemia
Descending Colon Cancer Familial Atrial Fibrillation
Heart Disease Hepatic Flexure Cancer
Hydronephrosis Intestinal Obstruction
Intestinal Perforation Iron Deficiency Anemia
Neutropenia Paralytic Ileus
Protein-Energy Malnutrition Rectosigmoid Junction Neoplasm
Small Intestine Cancer Splenic Flexure Cancer
Transverse Colon Cancer

Graphical network of the top 20 diseases related to Colorectal Cancer:



Diseases related to Colorectal Cancer

Symptoms & Phenotypes for Colorectal Cancer

Human phenotypes related to Colorectal Cancer:

30
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 renal cell carcinoma 30 HP:0005584
2 neoplasm of the stomach 30 HP:0006753
3 transitional cell carcinoma of the bladder 30 HP:0006740
4 uterine leiomyosarcoma 30 HP:0002891
5 hereditary nonpolyposis colorectal carcinoma 30 HP:0006716

Symptoms via clinical synopsis from OMIM®:

57 (Updated 08-Dec-2022)
Neoplasia:
colorectal cancer

Clinical features from OMIM®:

114500 (Updated 08-Dec-2022)

UMLS symptoms related to Colorectal Cancer:


nausea and vomiting; constipation; abdominal pain; diarrhea; dyspepsia; icterus; heartburn; gastrointestinal gas

GenomeRNAi Phenotypes related to Colorectal Cancer according to GeneCards Suite gene sharing:

25 (show top 50) (show all 54)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 11.1 BRAF PIK3CA
2 Decreased viability GR00055-A-2 11.1 BRAF PIK3CA
3 Decreased viability GR00221-A-1 11.1 BUB1B AKT1 PIK3CA FGFR3 NRAS PDGFRL
4 Decreased viability GR00221-A-2 11.1 BUB1B AKT1 CHEK2 DCC PIK3CA FGFR3
5 Decreased viability GR00221-A-3 11.1 BUB1B AKT1 CHEK2 DCC FGFR3 NRAS
6 Decreased viability GR00221-A-4 11.1 BRAF AKT1 CHEK2 DCC PIK3CA
7 Decreased viability GR00249-S 11.1 BRAF BUB1 AKT1 FGFR3
8 Decreased viability GR00301-A 11.1 BRAF BUB1 BUB1B MLH3
9 Decreased viability GR00342-S-2 11.1 CHEK2
10 Decreased viability GR00381-A-1 11.1 BRAF
11 Decreased viability GR00402-S-2 11.1 PIK3CA
12 Increased shRNA abundance (Z-score > 2) GR00366-A-1 10.36 CHEK2
13 Increased shRNA abundance (Z-score > 2) GR00366-A-10 10.36 FGFR3
14 Increased shRNA abundance (Z-score > 2) GR00366-A-112 10.36 CHEK2
15 Increased shRNA abundance (Z-score > 2) GR00366-A-114 10.36 CHEK2 FGFR3
16 Increased shRNA abundance (Z-score > 2) GR00366-A-117 10.36 AXIN2
17 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.36 CHEK2
18 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.36 FGFR3
19 Increased shRNA abundance (Z-score > 2) GR00366-A-123 10.36 CHEK2
20 Increased shRNA abundance (Z-score > 2) GR00366-A-133 10.36 APC
21 Increased shRNA abundance (Z-score > 2) GR00366-A-142 10.36 CHEK2
22 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.36 BRAF
23 Increased shRNA abundance (Z-score > 2) GR00366-A-169 10.36 EP300
24 Increased shRNA abundance (Z-score > 2) GR00366-A-182 10.36 EP300
25 Increased shRNA abundance (Z-score > 2) GR00366-A-192 10.36 APC
26 Increased shRNA abundance (Z-score > 2) GR00366-A-195 10.36 EP300
27 Increased shRNA abundance (Z-score > 2) GR00366-A-202 10.36 APC
28 Increased shRNA abundance (Z-score > 2) GR00366-A-213 10.36 AKT1
29 Increased shRNA abundance (Z-score > 2) GR00366-A-23 10.36 AXIN2
30 Increased shRNA abundance (Z-score > 2) GR00366-A-3 10.36 NRAS
31 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.36 AXIN2
32 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.36 BRAF CTNNB1
33 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.36 FGFR3
34 Increased shRNA abundance (Z-score > 2) GR00366-A-56 10.36 EP300
35 Increased shRNA abundance (Z-score > 2) GR00366-A-59 10.36 FGFR3
36 Increased shRNA abundance (Z-score > 2) GR00366-A-60 10.36 AKT1 PIK3CA AXIN2 CHEK2 FGFR3
37 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.36 FGFR3
38 Increased shRNA abundance (Z-score > 2) GR00366-A-65 10.36 EP300
39 Increased shRNA abundance (Z-score > 2) GR00366-A-67 10.36 EP300
40 Increased shRNA abundance (Z-score > 2) GR00366-A-70 10.36 AKT1
41 Increased shRNA abundance (Z-score > 2) GR00366-A-72 10.36 NRAS
42 Increased shRNA abundance (Z-score > 2) GR00366-A-79 10.36 EP300
43 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.36 AKT1 CHEK2 FGFR3
44 Increased shRNA abundance (Z-score > 2) GR00366-A-88 10.36 AXIN2
45 no effect GR00402-S-1 10.2 AKT1 APC AXIN2 BAX BRAF BUB1
46 no effect GR00402-S-2 10.2 AKT1 APC AXIN2 BAX BRAF BUB1
47 Decreased substrate adherent cell growth GR00193-A-1 10.19 BUB1
48 Decreased substrate adherent cell growth GR00193-A-2 10.19 BUB1
49 Decreased substrate adherent cell growth GR00193-A-3 10.19 BRAF BUB1 CHEK2 FGFR3
50 Decreased substrate adherent cell growth GR00193-A-4 10.19 BRAF BUB1 CHEK2

MGI Mouse Phenotypes related to Colorectal Cancer:

45 (show all 26)
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 10.55 AKT1 APC BAX BRAF BUB1 BUB1B
2 homeostasis/metabolism MP:0005376 10.5 AKT1 APC BAX BRAF BUB1 BUB1B
3 growth/size/body region MP:0005378 10.43 AKT1 APC AXIN2 BAX BRAF BUB1
4 cellular MP:0005384 10.42 AKT1 APC AXIN2 BAX BRAF BUB1
5 normal MP:0002873 10.4 AKT1 APC AXIN2 BRAF BUB1 CTNNB1
6 nervous system MP:0003631 10.38 AKT1 APC AXIN2 BAX BRAF CHEK2
7 endocrine/exocrine gland MP:0005379 10.36 AKT1 APC AXIN2 BAX BRAF BUB1
8 immune system MP:0005387 10.34 AKT1 APC BAX BRAF BUB1 BUB1B
9 embryo MP:0005380 10.31 AKT1 APC AXIN2 BRAF BUB1B CTNNB1
10 digestive/alimentary MP:0005381 10.3 APC AXIN2 BRAF BUB1B CTNNB1 DCC
11 muscle MP:0005369 10.29 AKT1 APC BAX BRAF BUB1B CTNNB1
12 cardiovascular system MP:0005385 10.29 AKT1 APC AXIN2 BRAF BUB1B CHEK2
13 behavior/neurological MP:0005386 10.27 AKT1 APC AXIN2 BAX BRAF BUB1
14 liver/biliary system MP:0005370 10.24 AKT1 APC BRAF BUB1 BUB1B CTNNB1
15 no phenotypic analysis MP:0003012 10.21 AXIN2 BUB1 CTNNB1 FGFR3 NRAS PIK3CA
16 reproductive system MP:0005389 10.21 AKT1 APC AXIN2 BAX BRAF BUB1
17 renal/urinary system MP:0005367 10.2 APC BAX BRAF CTNNB1 EP300 FGFR3
18 limbs/digits/tail MP:0005371 10.18 APC AXIN2 BAX BRAF CTNNB1 FGFR3
19 craniofacial MP:0005382 10.11 APC AXIN2 BRAF CTNNB1 EP300 FGFR3
20 pigmentation MP:0001186 10.1 APC BRAF CTNNB1 DCC NRAS TP53
21 respiratory system MP:0005388 10.1 AKT1 BAX BRAF BUB1B CTNNB1 DCC
22 skeleton MP:0005390 10.06 AKT1 APC AXIN2 BAX BRAF BUB1B
23 hematopoietic system MP:0005397 10.06 AKT1 APC BAX BRAF BUB1 BUB1B
24 vision/eye MP:0005391 10.03 APC AXIN2 BAX BRAF BUB1B CTNNB1
25 mortality/aging MP:0010768 9.89 AKT1 APC AXIN2 BAX BRAF BUB1
26 integument MP:0010771 9.32 AKT1 APC AXIN2 BRAF BUB1B CTNNB1

Drugs & Therapeutics for Colorectal Cancer

PubMed Health treatment related to Colorectal Cancer: 63

Surgery is performed to remove as much of the cancer as possible. In early stages, further treatment may not be needed. If the cancer is at a more advanced stage, further treatments like radiation therapy or chemotherapy are options.

Drugs for Colorectal Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 841)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ketamine Approved, Vet_approved Phase 4 6740-88-1, 1867-66-9 3821
2
Tramadol Approved, Investigational Phase 4 27203-92-5 33741 5523
3
Ferrous fumarate Approved Phase 4 141-01-5
4
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 12560
5
Iron isomaltoside 1000 Approved, Investigational Phase 4 1370654-58-2
6
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
7
Hydromorphone Approved, Illicit Phase 4 466-99-9, 71-68-1 5284570
8
Hydrocodone Approved, Illicit, Investigational Phase 4 125-29-1 5284569
9
Orphenadrine Approved Phase 4 83-98-7 4601
10
Azithromycin Approved Phase 4 83905-01-5 447043
11
Esomeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6, 119141-88-7 9568614 4594
12
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
13
Iron Approved Phase 4 7439-89-6 29936
14
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
15
Tocopherol Approved, Investigational Phase 4 1406-66-2
16
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
17
Darbepoetin alfa Approved, Investigational Phase 4 209810-58-2
18
Acetaminophen Approved Phase 4 103-90-2 1983
19
Glucagon Approved Phase 4 16941-32-5 16133228 16186314
20
Ertapenem Approved, Investigational Phase 4 153832-46-3 150610
21
Mitomycin Approved Phase 4 50-07-7 5746
22
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
23
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
24
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
25
Tranexamic acid Approved Phase 4 1197-18-8 5526
26
Racepinephrine Approved, Vet_approved Phase 4 51-43-4, 329-65-7 838 5816
27
Magnesium oxide Approved Phase 4 1309-48-4 14792
28
Droperidol Approved, Vet_approved Phase 4 548-73-2 3168
29
Framycetin Approved, Experimental, Vet_approved Phase 4 1404-04-2, 119-04-0, 3947-65-7 413349 8378
30
Sodium citrate Approved, Investigational Phase 4 68-04-2 23431961
31
Rivaroxaban Approved Phase 4 366789-02-8 9875401
32
Sodium sulfate Approved, Vet_approved Phase 4 7757-82-6
33
Panitumumab Approved, Investigational Phase 4 339177-26-3
34
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
35
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
36
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
37
Rofecoxib Approved, Investigational, Withdrawn Phase 4 162011-90-7 5090
38
Amphotericin B Approved, Investigational Phase 4 1397-89-3 5280965
39
Colistin Approved Phase 4 1264-72-8, 1066-17-7 5311054
40
Tobramycin Approved, Investigational Phase 4 32986-56-4 36294
41
DL-alpha-Tocopherol Approved, Experimental, Investigational, Nutraceutical, Vet_approved Phase 4 59-02-9, 10191-41-0 2116 14985
42
Arginine Approved, Investigational, Nutraceutical Phase 4 74-79-3 6322
43
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
44
Tocotrienol Investigational Phase 4 6829-55-6 9929901
45 Excitatory Amino Acid Antagonists Phase 4
46 Anticonvulsants Phase 4
47 Anesthetics, Dissociative Phase 4
48 Iron Supplement Phase 4
49 Cholinergic Antagonists Phase 4
50 Parenteral Nutrition Solutions Phase 4

Interventional clinical trials:

(show top 50) (show all 5924)
# Name Status NCT ID Phase Drugs
1 Insulin Therapy Reduce Post-Operative Inflammatory Response After Curative Colorectal Cancer Resection: Randomization Controlled Trial Unknown status NCT02746432 Phase 4 Hyper insulinemic euglycemic clamp
2 A Prospective,Randomized Control Trial of Intraoperative Intraportal Chemotherapy (5-FU and Oxaliplatin) Combined With Adjuvant Chemotherapy to Prevent Liver Metastasis in Patients Receiving Curative Colorectal Cancer Resection. Unknown status NCT01972503 Phase 4 5-FU and oxaliplatin
3 Raltitrexed and Oxaliplatin and Lipiodol Transcatheter Arterial Chemoembolization for Advanced Colorectal Cancer Unknown status NCT01959061 Phase 4 Raltitrexed;Oxaliplatin;lipiodol
4 An Open Label, Multicenter, Non-Comparative, Phase IV Study of Panitumumab to Characterize Its Safety, Tolerability and Activity in Indian Subjects With Previously Treated Wild-Type RAS (KRAS and NRAS), Metastatic Colorectal Cancer Unknown status NCT02301962 Phase 4 Panitumumab
5 Multicenter Randomized Controlled Trial Comparing Ferric(III)Carboxymaltose Infusion With Oral Iron Suppletion in the Treatment of Preoperative Anaemia in Colorectal Cancer Patients Unknown status NCT02243735 Phase 4 Ferrous fumarate;ferric(III)carboxymaltose
6 Maintenance Treatment With Capecitabine Metronomic Chemotherapy and Chinese Traditional Medicine in Metastatic Colorectal Cancer Unknown status NCT02575378 Phase 4 Metronimic chemotherapy plus Chinese Traditional Medicine;Metronimic chemotherapy
7 A Randomized Controlled Trial of TACE Hepatic Artery Infusion of Oxaliplatin and Raltitrexed Treatment of Colorectal Cancer With Liver Metastases Unknown status NCT02557490 Phase 4 oxaliplatin and raltitrexed
8 TAC vs TACE Plus folfox4 as the Treatment of Unresectalbe Liver Metastasis of Colorectal Cancer With Resection of the Primary Tumor: a Prospective, Randomized, Control Trial Unknown status NCT00868569 Phase 4
9 Preoperative Transhepatic Arterial Chemotherapy in the Treatment of Liver Metastasis of Resectable Colorectal Cancer Unknown status NCT00874406 Phase 4 tac + folfox4;folfox4
10 A Prospective, Randomized, One-center Study Assessing Overall Survival Using RFA Plus Chemotherapy ± Target Therapy and Chemotherapy ± Target Therapy Alone in Patients With Unresectable Unresectable Colorectal Cancer Liver Metastases Unknown status NCT03127072 Phase 4 chemotherapy ± target therapy
11 VASCular Impact of Angiogenic Treatment in Patients With Advanced Colorectal Cancer Unknown status NCT04813913 Phase 4 Bevacizumab in combination with chemotherapy based on fluoropyrimidine IV
12 A Randomized Study Of Continuous FOLFOX4 vs. FOLFOX4 in a Stop-and-Go Fashion in 1st Line Advanced Colorectal Cancer Unknown status NCT01023633 Phase 4 Oxaliplatin, LV, 5-FU
13 Non-randomized Phase-IV-study to Investigate the Efficacy of FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema Unknown status NCT01315990 Phase 4 FOLFIRI + Cetuximab
14 Erythromycin as a Novel Therapy Against Familial Adenomatous Polyposis and Sporadic Colorectal Cancer by APC Nonsense Mutation Readthrough. Unknown status NCT02175914 Phase 4 Erythromycin
15 Study of Cetuximab in Combination With Chemotherapy for the First Treatment of Metastatic Colorectal Cancer Unknown status NCT01564810 Phase 4 Cetuximab;chemotherapy of mFOLFOX6 or FOLFIRI
16 A Prospective Evaluation of Capecitabine and Metabolite Pharmacokinetics in Elderly Breast and Colorectal Cancer Patients and Their Association With Toxicity and Molecular Markers of Enzyme Activity and Aging Unknown status NCT03465202 Phase 4 Capecitabine
17 NK Activity Modulation by Intravenous Lidocaine During Laparoscopic Colorectal Surgery Unknown status NCT01841294 Phase 4 Intravenous Lidocaine;Normal saline infusion
18 Phase 4 of Efficacy and Patient Satisfaction of Miralax and Gatorade Versus Movi Prep Unknown status NCT01695863 Phase 4 comparing 2 drugs on their effect on the bowel preparation for colonoscopy
19 Enhancing the Anabolic Effect of Perioperative Nutrition With Insulin While Maintaining Normoglycemia Unknown status NCT02032953 Phase 4 Insulin
20 Preoperative Assessment of Colon Tumor: A Prospective, Blinded Study. Unknown status NCT00114829 Phase 4
21 Investigation of Association Between UGT1A1 Polymorphisms and Irinotecan Toxicity in Korean Patients With Advanced Colorectal or Gastric Cancer Treated With FOLFIRI Regimen Unknown status NCT01271582 Phase 4 Irinotecan, 5FU, leucovorin
22 A Phase II Study of Tegafur-Uracil as Maintenance Chemotherapy in Patients With Stage II Microsatellite-Stable or Low-Level Microsatellite-Instability Colon Cancer Unknown status NCT02887365 Phase 4 tegafur-uracil
23 Multimodal Narcotic Limited Perioperative Pain Control With Colorectal Surgery as Part of an Enhanced Recovery After Surgery Protocol: A Randomized Prospective Single- Center Trial. Unknown status NCT02958566 Phase 4 Acetaminophen;Gabapentin;Orphenadrine;Lidocaine;Marcaine;Ketamine;Methadone;Tramadol;Ketorolac;Morphine Sulfate;Fentanyl;Dilaudid;Hydrocodone-Acetaminophen Tab 5-325 MG;HYDROCODONE/ACETAMINOPHEN 5 Mg-325 Mg ORAL TABLET
24 Implementation of Pre-emptive Geno- and Phenotyping in 5-Fluorouracil- or Capecitabine-treated Patients With the Aim of Reducing Toxicity Unknown status NCT04269369 Phase 4 5-Fluorouracil
25 The Impact of Treatment of Anaemia With Intravenous Iron on Haematological Values for Patients After Colorectal Surgery Unknown status NCT02999217 Phase 4 Iron isomaltoside;Saline
26 Randomized, Parallel Group, Clinical Trial Comparing Intravenous Iron Sucrose Versus Oral Ferrous Sulphate in the Treatment of Perioperative Iron Deficiency in Patients With Colo-Rectal Neoplasm and Iron Deficiency Anemia. Unknown status NCT00199277 Phase 4 i.v. iron sucrose;Oral iron
27 Azithromycin Treatment for Readthrough of APC Gene Stop Codon Mutations in Familial Adenomatous Polyposis Unknown status NCT04454151 Phase 4 Azithromycin Tablets
28 Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutation in Familial Adenomatous Polyposis-protocol is Identical to Study No. 0519-10-TLV- Minors' Adjusted Version Unknown status NCT02354560 Phase 4 Erythromycin
29 Evaluate the Safety of Combination of Orectalip® (Oxaliplatin), Fluorouracil and Leucovorin as Adjuvant Treatment for High-risk Stage-Ⅱ Colorectal Cancer Completed NCT02284529 Phase 4 Orectalip
30 A Prospective, Randomized, Control Trial of Oxaliplatine Based Adjuvant Chemotherapy for Stage II/III Colorectal Cancer: 8 Cycles vs 12 Cycles Completed NCT00868816 Phase 4 12 cycles of oxaliplatine based adjuvant chemotherapy;8 cycles of oxaliplatine based adjuvant chemotherapy
31 An Open Label Study to Determine the Efficacy of Ferric Carboxymaltose in Preoperative Colorectal Cancer Related Anaemia, and to Develop Biomarkers to Predict Response to This Treatment Strategy Completed NCT01701310 Phase 4 Ferric carboxymaltose;Ferrous Sulphate
32 Preoperative Treatment With NSAID in Colorectal Cancer Patients in Relationship to Tumor Host Reactions Completed NCT00473980 Phase 4 Indomethacin, celecoxib, esomeprazole
33 Postoperative folfox4 Only vs folfox4 Plus TAC in the Treatment Unresectable Liver Metastasis of Colorectal Cancer: a Randomized,Prospective,Control Trial Completed NCT00869271 Phase 4
34 Multi-center, Randomized Comparison Study to eVALUatE Outcomes and Resource Needs of Imaging and Treatment Following Primovist-enhanced MRI of the Liver in Comparison to Extracellular Contrast Media (ECCM)-Enhanced MRI and Contrast-enhanced Computed Tomography (CT) in Patients With a History of Colorectal Cancer and Known or Suspected Metachronous Liver Metastases. Completed NCT00764621 Phase 4
35 Phase 4 Study to Characterize and Evaluate Markers of Chemoresistance in Patients With Metastatic Colorectal Cancer Completed NCT00559676 Phase 4 capecitabine;fluorouracil;irinotecan hydrochloride;leucovorin calcium;oxaliplatin
36 Single-blinded, Randomized, Controlled Trial About the Effects of n-3 LCPUFAs on Weight and Functional Status in Patients With Colorectal Cancer. Completed NCT04699760 Phase 4
37 An Open-label Study of the Safety, Tolerability, and Response Rate of Xeloda in Treatment-naïve Patients With Metastatic Colorectal Cancer Completed NCT02567331 Phase 4 Capecitabine
38 A Multi-Center, Single-Arm, Pilot Study of 5-FU Based Doublet Chemotherapy Plus Bevacizumab as Neoadjuvant Therapy for Patients With Previously Untreated Unresectable Liver-Only Metastases From Colorectal Cancer Completed NCT01695772 Phase 4 5-FU based doublet chemotherapy;bevacizumab
39 Dissemination of Colorectal Cancer Screening to Primary Care Physicians Completed NCT00441311 Phase 4
40 The Effect of Darbepoetin Alfa Treatment Upon the Rehabilitation Following Planned Surgery for Colorectal Cancer Completed NCT00122720 Phase 4 Darbepoetin Alfa
41 The Efficacy of Silymarin as Adjuvant Therapy on Colorectal Cancer Patients Undergoing FOLFIRI Treatment Completed NCT03130634 Phase 4 Silymarin
42 Evaluation of the Efficacy and Safety of Single Dose Tranexamic Acid in Reducing Blood Loss During Colorectal Cancer Surgery Completed NCT03606785 Phase 4 Tranexamic Acid Injection;placebo injection
43 Pharmacogenetics and Therapeutic Drug Monitoring for the Optimization of Fluoropyrimidine Treatment in Patients With Advanced Colorectal Cancer Completed NCT01641458 Phase 4
44 Study of the Oxidative Stress in Patients With Colorectal Cancer. Open vs Laparoscopic Approach Completed NCT00928928 Phase 4
45 The Multi-center,Open-label,Single Arm Phase IV Clinical Trial of Efficacy and Safety of PEG-rhG-CSF in Patients With Lung Cancer,Head and Neck Cancer,Colorectal Cancer,Ovarian Cancer and the Other Cancer Receiving Chemotherapy Completed NCT02805166 Phase 4 PEG-rhG-CSF
46 The Effects of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib in Patients With Metastatic Colorectal Cancer (mCRC) or Gastrointestinal Stromal Tumour (GIST) Completed NCT02800330 Phase 4 Esomeprazole 40mg concomitantly;Esomeprazole 40mg before;Regorafenib 160mg or 120mg
47 An Australian Translational Study to Evaluate the Prognostic Role of Inflammatory Markers in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab (Avastin™) Completed NCT01588990 Phase 4 Oxaliplatin;Capecitabine;Bevacizumab;Leucovorin;5-Fluouracil;Irinotecan
48 Phase 4 Study to Evaluate Correlation of Overall Response According to RECIST-conventional Imaging Techniques, Morphologic Response by CT, & Histopathologic Response in Patients With Hepatic Metastasis Secondary to Colorectal Cancer With Bevacizumab in Combination With XELOX Completed NCT01493713 Phase 4
49 Effectiveness of Colon Capsule Endoscopy as Colorectal Cancer Method of Screening in The Familiar-Risk Population Completed NCT01557101 Phase 4
50 A Prospective Randomized Trial of Transversus Abdominis Plane (TAP) INtraoperative Block With Bupivacaine/Dexamethasone aGainst Liposomal Bupivacaine (Exparel®): the TINGLE Trial Completed NCT03723447 Phase 4 Liposomal bupivacaine;Bupivacaine/epinephrine/dexamethasone

Search NIH Clinical Center for Colorectal Cancer

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Aldesleukin
capecitabine
Carmustine
Floxuridine
Fluorouracil
Interferon Alfa-2a
Interferon Alfa-2b
INTERFERON ALFA-3N,HUMAN LEUKOCYTE DERIVED
interferon alfacon-1
Interferon gamma-1b
Interferons
irinotecan
Irinotecan hydrochloride
Levamisole
Lomustine
oxaliplatin
peginterferon alfa-2a
peginterferon alfa-2b
Recombinant interferon beta-1a
Recombinant interferon beta-1b
regorafenib

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Colorectal Cancer cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Colorectal Cancer:
Tumor infiltrating lymphocytes (TILs) for solid tumors
Embryonic/Adult Cultured Cells Related to Colorectal Cancer:
Tumor infiltrating lymphocytes PMIDs: 24329789 19342963 21498393 22996367 19304471 22555974 15800326 23650429 21325070 8170938 12242449 24218514 23904171

Cochrane evidence based reviews: colonic neoplasms

Genetic Tests for Colorectal Cancer

Genetic tests related to Colorectal Cancer:

# Genetic test Affiliating Genes
1 Carcinoma of Colon 28
2 Colorectal Cancer 28 AKT1 APC AURKA AXIN2 BAX BRAF BUB1 BUB1B CCND1 CHEK2 CTNNB1 DCC DLC1 EP300 FGFR3 FLCN MCC MLH3 NRAS PDGFRL PIK3CA PLA2G2A PTPN12 PTPRJ RAD54B SRC TLR2 TP53
3 Colon Cancer 28
4 Colorectal Carcinoma 28
5 Colorectal Cancer, Susceptibility to 28

Anatomical Context for Colorectal Cancer

Organs/tissues related to Colorectal Cancer:

FMA: Colon, Colon, Rectum
MalaCards : Colon, Liver, Lymph Node, T Cells, Small Intestine, Breast, Lung
ODiseA: Kidney

Publications for Colorectal Cancer

Articles related to Colorectal Cancer:

(show top 50) (show all 65289)
# Title Authors PMID Year
1
Loss-of-function mutations in PPAR gamma associated with human colon cancer. 53 62 57 5
10394368 1999
2
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. 62 57 5
22281684 2012
3
Microsatelite GT polymorphism in the toll-like receptor 2 is associated with colorectal cancer. 62 57 5
16879199 2006
4
Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. 53 57 5
12198537 2002
5
High frequency of mutations of the PIK3CA gene in human cancers. 57 5
15016963 2004
6
Microsatellite instability in colorectal cancer-the stable evidence. 53 62 57
20142816 2010
7
BRAF mutation in metastatic colorectal cancer. 53 62 5
19571295 2009
8
MYH mutations in patients with attenuated and classic polyposis and with young-onset colorectal cancer without polyps. 53 62 5
15236166 2004
9
Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. 53 62 57
12637750 2003
10
Cyclin D1 polymorphism and increased risk of colorectal cancer at young age. 53 62 5
11459873 2001
11
APC I1307K increases risk of transition from polyp to colorectal carcinoma in Ashkenazi Jews. 53 62 5
11159880 2001
12
Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. 53 62 5
1651563 1991
13
The Fanconi anemia DNA damage repair pathway in the spotlight for germline predisposition to colorectal cancer. 62 5
27165003 2016
14
Germline Mutations in FAN1 Cause Hereditary Colorectal Cancer by Impairing DNA Repair. 62 57
26052075 2015
15
TP53 loss creates therapeutic vulnerability in colorectal cancer. 62 57
25901683 2015
16
MUTYH-associated colorectal cancer and adenomatous polyposis. 62 5
23605219 2014
17
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. 62 57
24024839 2013
18
Genomics and epigenomics of colorectal cancer. 62 57
23325509 2013
19
Recurrent R-spondin fusions in colon cancer. 62 57
22895193 2012
20
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. 62 57
22722830 2012
21
Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. 62 57
22270724 2012
22
Expression of a mutant HSP110 sensitizes colorectal cancer cells to chemotherapy and improves disease prognosis. 62 57
21946539 2011
23
Germline PKHD1 mutations are protective against colorectal cancer. 62 57
21274727 2011
24
Colorectal adenomas and cancer link to chromosome 13q22.1-13q31.3 in a large family with excess colorectal cancer. 62 57
20522424 2010
25
Oncofetal H19-derived miR-675 regulates tumor suppressor RB in human colorectal cancer. 53 62 46
19926638 2010
26
Adenine removal activity and bacterial complementation with the human MutY homologue (MUTYH) and Y165C, G382D, P391L and Q324R variants associated with colorectal cancer. 62 5
19836313 2009
27
Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells. 53 62 46
19734943 2009
28
Mechanism of growth inhibition by MicroRNA 145: the role of the IGF-I receptor signaling pathway. 53 62 46
19391107 2009
29
Increased colorectal cancer incidence in obligate carriers of heterozygous mutations in MUTYH. 62 5
19394335 2009
30
Germline MutY human homologue mutations and colorectal cancer: a multisite case-control study. 62 5
19245865 2009
31
A transposon-based genetic screen in mice identifies genes altered in colorectal cancer. 62 57
19251594 2009
32
Deregulated expression of miR-106a predicts survival in human colon cancer patients. 53 62 46
18521848 2008
33
Characterization of mutant MUTYH proteins associated with familial colorectal cancer. 62 5
18534194 2008
34
Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. 53 62 46
18519671 2008
35
MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. 53 62 46
17968323 2008
36
Micro RNA 145 targets the insulin receptor substrate-1 and inhibits the growth of colon cancer cells. 53 62 46
17827156 2007
37
Identification of MYH mutation carriers in colorectal cancer: a multicenter, case-control, population-based study. 62 5
17368238 2007
38
CHEK2 I157T associates with familial and sporadic colorectal cancer. 62 5
16816021 2006
39
Differentially regulated micro-RNAs and actively translated messenger RNA transcripts by tumor suppressor p53 in colon cancer. 53 62 46
16609010 2006
40
BRAF mutations in colorectal carcinoma suggest two entities of microsatellite-unstable tumors. 53 5
16015629 2005
41
Colorectal cancer: mutations in a signalling pathway. 62 57
16094359 2005
42
Germline susceptibility to colorectal cancer due to base-excision repair gene defects. 62 5
15931596 2005
43
EphB receptor activity suppresses colorectal cancer progression. 62 57
15973414 2005
44
PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. 53 5
15608678 2005
45
Mutation of the PIK3CA gene in ovarian and breast cancer. 53 5
15520168 2004
46
BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. 53 5
15342696 2004
47
The CHEK2 1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotype. 62 5
12690581 2003
48
Hereditary colorectal cancer. 62 57
12621137 2003
49
A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. 62 57
12621132 2003
50
BLM heterozygosity and the risk of colorectal cancer. 62 57
12242432 2002

Variations for Colorectal Cancer

ClinVar genetic disease variations for Colorectal Cancer:

5 (show top 50) (show all 1377)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 ARID1A NM_006015.6(ARID1A):c.1653C>G (p.Tyr551Ter) SNV Association
523633 rs1553149467 GRCh37: 1:27057945-27057945
GRCh38: 1:26731454-26731454
2 ADAR NM_001111.5(ADAR):c.3020-759A>G SNV Protective
1342841 GRCh37: 1:154559598-154559598
GRCh38: 1:154587122-154587122
3 BRAF NM_004333.6(BRAF):c.1799T>A (p.Val600Glu) SNV Other
Pathogenic
13961 rs113488022 GRCh37: 7:140453136-140453136
GRCh38: 7:140753336-140753336
4 APC NM_000038.6(APC):c.3920T>A (p.Ile1307Lys) SNV Uncertain Significance; Risk Factor
Risk Factor
Risk Factor
822 rs1801155 GRCh37: 5:112175211-112175211
GRCh38: 5:112839514-112839514
5 ATM, C11orf65 NM_000051.4(ATM):c.8101del (p.Lys2700_Ile2701insTer) DEL Pathogenic
998127 rs2086682689 GRCh37: 11:108205782-108205782
GRCh38: 11:108335055-108335055
6 FGFR2 NM_000141.5(FGFR2):c.1672+1del DEL Pathogenic
998141 rs1847174277 GRCh37: 10:123258008-123258008
GRCh38: 10:121498494-121498494
7 MSH6 NM_000179.3(MSH6):c.2079del (p.Lys693fs) DEL Pathogenic
567689 rs267608083 GRCh37: 2:48027196-48027196
GRCh38: 2:47800057-47800057
8 MSH2 NM_000251.3(MSH2):c.1552_1553del (p.Gln518fs) MICROSAT Pathogenic
90697 rs63749930 GRCh37: 2:47693836-47693837
GRCh38: 2:47466697-47466698
9 MSH2 NM_000251.3(MSH2):c.1906G>C (p.Ala636Pro) SNV Pathogenic
1764 rs63750875 GRCh37: 2:47702310-47702310
GRCh38: 2:47475171-47475171
10 MSH6 NM_000179.3(MSH6):c.3514dup (p.Arg1172fs) DUP Pathogenic
89404 rs63751327 GRCh37: 2:48032123-48032124
GRCh38: 2:47804984-47804985
11 MSH2 NM_000251.3(MSH2):c.560T>C (p.Leu187Pro) SNV Pathogenic
91134 rs63751444 GRCh37: 2:47637426-47637426
GRCh38: 2:47410287-47410287
12 BRCA2 NM_000059.4(BRCA2):c.6468_6469del (p.Gln2157fs) MICROSAT Pathogenic
38047 rs80359596 GRCh37: 13:32914954-32914955
GRCh38: 13:32340817-32340818
13 EP300 NC_000022.11:g.(?_41154975)_(41164150_?)del DEL Pathogenic
Pathogenic
655763 GRCh37: 22:41550979-41560154
GRCh38: 22:41154975-41164150
14 EP300 NC_000022.11:g.(?_41151813)_(41152370_?)del DEL Pathogenic
Pathogenic
831260 GRCh37: 22:41547817-41548374
GRCh38:
15 EP300 NC_000022.11:g.(?_41131368)_(41140277_?)del DEL Pathogenic
Pathogenic
832045 GRCh37: 22:41527372-41536281
GRCh38:
16 APC NM_000038.6(APC):c.3927_3931del (p.Glu1309fs) MICROSAT Pathogenic
Pathogenic
816 rs121913224 GRCh37: 5:112175212-112175216
GRCh38: 5:112839515-112839519
17 APC NM_000038.6(APC):c.5490_5493del (p.Asn1830fs) DEL Pathogenic
181835 rs730881273 GRCh37: 5:112176779-112176782
GRCh38: 5:112841082-112841085
18 TP53 NM_000546.6(TP53):c.637C>T (p.Arg213Ter) SNV Pathogenic
43590 rs397516436 GRCh37: 17:7578212-7578212
GRCh38: 17:7674894-7674894
19 TP53 NM_000546.6(TP53):c.524G>A (p.Arg175His) SNV Pathogenic
Pathogenic
12374 rs28934578 GRCh37: 17:7578406-7578406
GRCh38: 17:7675088-7675088
20 TP53 NM_000546.6(TP53):c.581T>G (p.Leu194Arg) SNV Pathogenic
376633 rs1057519998 GRCh37: 17:7578268-7578268
GRCh38: 17:7674950-7674950
21 TP53 NM_000546.6(TP53):c.733G>A (p.Gly245Ser) SNV Pathogenic
12365 rs28934575 GRCh37: 17:7577548-7577548
GRCh38: 17:7674230-7674230
22 TP53 NM_000546.6(TP53):c.844C>T (p.Arg282Trp) SNV Pathogenic
12364 rs28934574 GRCh37: 17:7577094-7577094
GRCh38: 17:7673776-7673776
23 MUTYH NM_001048174.2(MUTYH):c.849+3A>C SNV Pathogenic
Uncertain Significance
135992 rs587780751 GRCh37: 1:45797835-45797835
GRCh38: 1:45332163-45332163
24 APC NM_000038.6(APC):c.637C>T (p.Arg213Ter) SNV Pathogenic
Pathogenic
140952 rs587781392 GRCh37: 5:112116592-112116592
GRCh38: 5:112780895-112780895
25 MLH1 NM_000249.4(MLH1):c.793C>A (p.Arg265Ser) SNV Pathogenic
90380 rs63751194 GRCh37: 3:37058999-37058999
GRCh38: 3:37017508-37017508
26 MSH6 NM_000179.3(MSH6):c.2150_2153del (p.Val717fs) DEL Pathogenic
89256 rs267608058 GRCh37: 2:48027269-48027272
GRCh38: 2:47800130-47800133
27 MSH6 NM_000179.3(MSH6):c.2569_2572del (p.Asp857fs) DEL Pathogenic
89290 rs587779243 GRCh37: 2:48027688-48027691
GRCh38: 2:47800549-47800552
28 MUTYH NM_001048174.2(MUTYH):c.383G>A (p.Trp128Ter) SNV Pathogenic
230971 rs762307622 GRCh37: 1:45798627-45798627
GRCh38: 1:45332955-45332955
29 APC NM_000038.6(APC):c.3183_3187del (p.Lys1061_Gln1062insTer) DEL Pathogenic
88913 rs587779352 GRCh37: 5:112174471-112174475
GRCh38: 5:112838774-112838778
30 MLH1 NM_000249.4(MLH1):c.790+4A>G SNV Pathogenic
90363 rs267607786 GRCh37: 3:37056039-37056039
GRCh38: 3:37014548-37014548
31 MLH1 NM_000249.4(MLH1):c.883A>C (p.Ser295Arg) SNV Pathogenic
90408 rs63751598 GRCh37: 3:37059089-37059089
GRCh38: 3:37017598-37017598
32 MSH6 NM_000179.3(MSH6):c.2731C>T (p.Arg911Ter) SNV Pathogenic
89312 rs63751017 GRCh37: 2:48027853-48027853
GRCh38: 2:47800714-47800714
33 MLH1 NM_000249.4(MLH1):c.2035G>T (p.Glu679Ter) SNV Pathogenic
90005 rs587778971 GRCh37: 3:37090440-37090440
GRCh38: 3:37048949-37048949
34 MSH6 NM_000179.3(MSH6):c.3202C>T (p.Arg1068Ter) SNV Pathogenic
89352 rs63749843 GRCh37: 2:48030588-48030588
GRCh38: 2:47803449-47803449
35 MSH2 NM_000251.3(MSH2):c.1165C>T (p.Arg389Ter) SNV Pathogenic
90557 rs587779075 GRCh37: 2:47656969-47656969
GRCh38: 2:47429830-47429830
36 MSH2 NM_000251.3(MSH2):c.1786_1788del (p.Asn596del) DEL Pathogenic
1757 rs63749831 GRCh37: 2:47702190-47702192
GRCh38: 2:47475051-47475053
37 MSH6 NM_000179.3(MSH6):c.2062_2063del (p.Val688fs) MICROSAT Pathogenic
89247 rs63750075 GRCh37: 2:48027181-48027182
GRCh38: 2:47800042-47800043
38 MSH2 NM_000251.3(MSH2):c.942+3A>T SNV Pathogenic
36580 rs193922376 GRCh37: 2:47641560-47641560
GRCh38: 2:47414421-47414421
39 MSH6 NM_000179.3(MSH6):c.10C>T (p.Gln4Ter) SNV Pathogenic
183723 rs786201042 GRCh37: 2:48010382-48010382
GRCh38: 2:47783243-47783243
40 MLH1 NM_000249.4(MLH1):c.244A>G (p.Thr82Ala) SNV Pathogenic
90116 rs587778998 GRCh37: 3:37042482-37042482
GRCh38: 3:37000991-37000991
41 MLH1 NM_000249.4(MLH1):c.1459C>T (p.Arg487Ter) SNV Pathogenic
89744 rs63749795 GRCh37: 3:37070324-37070324
GRCh38: 3:37028833-37028833
42 MSH6 NM_000179.3(MSH6):c.1571dup (p.Tyr524Ter) DUP Pathogenic
433910 rs1553412966 GRCh37: 2:48026692-48026693
GRCh38: 2:47799553-47799554
43 FLCN NM_144997.7(FLCN):c.1429C>T (p.Arg477Ter) SNV Pathogenic
253251 rs879255678 GRCh37: 17:17118502-17118502
GRCh38: 17:17215188-17215188
44 FGFR3 NM_000142.5(FGFR3):c.742C>T (p.Arg248Cys) SNV Pathogenic
16332 rs121913482 GRCh37: 4:1803564-1803564
GRCh38: 4:1801837-1801837
45 FGFR3 NM_000142.5(FGFR3):c.746C>G (p.Ser249Cys) SNV Pathogenic
16339 rs121913483 GRCh37: 4:1803568-1803568
GRCh38: 4:1801841-1801841
46 FGFR3 NM_000142.5(FGFR3):c.749C>G (p.Pro250Arg) SNV Pathogenic
16340 rs4647924 GRCh37: 4:1803571-1803571
GRCh38: 4:1801844-1801844
47 FGFR3 NM_000142.5(FGFR3):c.1138G>A (p.Gly380Arg) SNV Pathogenic
16327 rs28931614 GRCh37: 4:1806119-1806119
GRCh38: 4:1804392-1804392
48 FGFR3 NM_000142.5(FGFR3):c.1620C>G (p.Asn540Lys) SNV Pathogenic
16338 rs28933068 GRCh37: 4:1807371-1807371
GRCh38: 4:1805644-1805644
49 FGFR3 NM_000142.5(FGFR3):c.1949A>C (p.Lys650Thr) SNV Pathogenic
65855 rs121913105 GRCh37: 4:1807890-1807890
GRCh38: 4:1806163-1806163
50 TP53 NM_000546.6(TP53):c.743G>A (p.Arg248Gln) SNV Pathogenic
Pathogenic
12356 rs11540652 GRCh37: 17:7577538-7577538
GRCh38: 17:7674220-7674220

UniProtKB/Swiss-Prot genetic disease variations for Colorectal Cancer:

73 (show all 27)
# Symbol AA change Variation ID SNP ID
1 BRAF p.Arg462Ile VAR_018613 rs180177032
2 BRAF p.Ile463Ser VAR_018614 rs180177033
3 BRAF p.Gly464Glu VAR_018615 rs121913348
4 BRAF p.Val600Glu VAR_018629 rs113488022
5 BRAF p.Lys601Glu VAR_018630 rs121913364
6 CTNNB1 p.Ser33Tyr VAR_017619 rs121913400
7 MLH1 p.Ala681Thr VAR_004466 rs63750217
8 MLH1 p.Cys77Tyr VAR_012904 rs63750437
9 MLH1 p.Glu268Gly VAR_012915 rs63750650
10 MLH1 p.Asp132His VAR_022665 rs28930073
11 MLH1 p.Gly67Glu VAR_038024 rs63749939
12 MLH1 p.Leu260Arg VAR_043401 rs63751283
13 MLH1 p.Lys618Arg VAR_043424 rs63750449
14 MLH1 p.Leu749Pro VAR_043437 rs267607894
15 MSH2 p.Asp506Tyr VAR_012941 rs63750492
16 MSH6 p.Gly566Arg VAR_012959 rs63749973
17 MSH6 p.Val800Ala VAR_043960 rs63750895
18 MT-CO1 p.Gly125Asp VAR_064154 rs281865417
19 MT-CO1 p.Ser458Pro VAR_064155 rs267606884
20 PDGFRL p.His23Tyr VAR_026052 rs137853148
21 PIK3CA p.Arg38His VAR_026166 rs772110575
22 PIK3CA p.Gly106Val VAR_026168 rs1057519930
23 PIK3CA p.Glu453Gln VAR_026172 rs1057519925
24 PIK3CA p.Glu542Lys VAR_026173 rs121913273
25 PIK3CA p.Glu545Lys VAR_026178 rs104886003
26 PIK3CA p.Met1043Ile VAR_026190 rs121913283
27 PIK3CA p.His1047Arg VAR_026192 rs121913279

Cosmic variations for Colorectal Cancer:

8 (show top 50) (show all 747)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM87804055 KRAS large intestine,colon,other,ulcerative colitis c.35G>T p.G12V 12:25245350-25245350 27
2 COSM134990131 KRAS large intestine,colon,other,ulcerative colitis c.38G>A p.G13D 12:25245347-25245347 27
3 COSM87811077 KRAS large intestine,colon,other,ulcerative colitis c.37G>A p.G13S 12:25245348-25245348 27
4 COSM91865142 KRAS large intestine,colon,other,ulcerative colitis c.37G>A p.G13S 12:25245348-25245348 27
5 COSM134995752 KRAS large intestine,colon,other,ulcerative colitis c.37G>A p.G13S 12:25245348-25245348 27
6 COSM134622234 KRAS large intestine,colon,other,ulcerative colitis c.37G>A p.G13S 12:25245348-25245348 27
7 COSM93183877 TP53 large intestine,colon,adenoma,NS c.733G>A p.G245S 17:7674230-7674230 25
8 COSM142564162 TP53 large intestine,colon,adenoma,NS c.524A>G p.H175R 17:7674890-7674890 25
9 COSM144314088 TP53 large intestine,colon,adenoma,NS c.-87A>C p.? 17:7675221-7675221 25
10 COSM144104972 TP53 large intestine,colon,adenoma,NS c.256G>C p.G86R 17:7674230-7674230 25
11 COSM122567711 TP53 large intestine,colon,adenoma,NS c.-6A>C p.? 17:7675221-7675221 25
12 COSM121876212 TP53 large intestine,colon,adenoma,NS c.337G>A p.G113S 17:7674230-7674230 25
13 COSM143943997 TP53 large intestine,colon,adenoma,NS c.256G>A p.G86S 17:7674230-7674230 25
14 COSM145017865 TP53 large intestine,colon,adenoma,NS c.616G>A p.G206S 17:7674230-7674230 25
15 COSM111758775 TP53 large intestine,colon,adenoma,NS c.733G>A p.G245S 17:7674230-7674230 25
16 COSM145021980 TP53 large intestine,colon,adenoma,NS c.524A>G p.H175R 17:7674890-7674890 25
17 COSM112253807 TP53 large intestine,colon,adenoma,NS c.733G>A p.G245S 17:7674230-7674230 25
18 COSM145282365 TP53 large intestine,colon,adenoma,NS c.274A>C p.N92H 17:7675221-7675221 25
19 COSM144947428 TP53 large intestine,colon,adenoma,NS c.274A>C p.N92H 17:7675221-7675221 25
20 COSM142560476 TP53 large intestine,colon,adenoma,NS c.616G>A p.G206S 17:7674230-7674230 25
21 COSM93184097 TP53 large intestine,colon,adenoma,NS c.916C>T p.R306* 17:7673704-7673704 25
22 COSM144351508 TP53 large intestine,colon,adenoma,NS c.820G>C p.E274Q 17:7673767-7673767 25
23 COSM122291262 TP53 large intestine,colon,adenoma,NS c.457G>C p.E153Q 17:7673767-7673767 25
24 COSM121881087 TP53 large intestine,colon,adenoma,NS c.245A>G p.H82R 17:7674890-7674890 25
25 COSM143371076 TP53 large intestine,colon,adenoma,NS c.616G>A p.G206S 17:7674230-7674230 25
26 COSM143175784 TP53 large intestine,colon,adenoma,NS c.256G>C p.G86R 17:7674230-7674230 25
27 COSM87925845 TP53 large intestine,colon,adenoma,NS c.733G>C p.G245R 17:7674230-7674230 25
28 COSM87902864 TP53 large intestine,colon,adenoma,NS c.641A>G p.H214R 17:7674890-7674890 25
29 COSM142854442 TP53 large intestine,colon,adenoma,NS c.733G>C p.G245R 17:7674230-7674230 25
30 COSM122734486 TP53 large intestine,colon,adenoma,NS c.520C>T p.R174* 17:7673704-7673704 25
31 COSM93566065 TP53 large intestine,colon,adenoma,NS c.853G>C p.E285Q 17:7673767-7673767 25
32 COSM122271907 TP53 large intestine,colon,adenoma,NS c.520C>T p.R174* 17:7673704-7673704 25
33 COSM143210532 TP53 large intestine,colon,adenoma,NS c.853G>C p.E285Q 17:7673767-7673767 25
34 COSM112024216 TP53 large intestine,colon,adenoma,NS c.391A>C p.N131H 17:7675221-7675221 25
35 COSM144087350 TP53 large intestine,colon,adenoma,NS c.439C>T p.R147* 17:7673704-7673704 25
36 COSM122169742 TP53 large intestine,colon,adenoma,NS c.-6A>C p.? 17:7675221-7675221 25
37 COSM88223016 TP53 large intestine,colon,adenoma,NS c.391A>C p.N131H 17:7675221-7675221 25
38 COSM93453030 TP53 large intestine,colon,adenoma,NS c.391A>C p.N131H 17:7675221-7675221 25
39 COSM106053362 TP53 large intestine,colon,adenoma,NS c.733G>A p.G245S 17:7674230-7674230 25
40 COSM111763021 TP53 large intestine,colon,adenoma,NS c.641A>G p.H214R 17:7674890-7674890 25
41 COSM144034535 TP53 large intestine,colon,adenoma,NS c.700G>C p.G234R 17:7674230-7674230 25
42 COSM144281949 TP53 large intestine,colon,adenoma,NS c.376G>C p.E126Q 17:7673767-7673767 25
43 COSM87898578 TP53 large intestine,colon,adenoma,NS c.733G>A p.G245S 17:7674230-7674230 25
44 COSM144674934 TP53 large intestine,colon,adenoma,NS c.616G>C p.G206R 17:7674230-7674230 25
45 COSM105620519 TP53 large intestine,colon,adenoma,NS c.733G>A p.G245S 17:7674230-7674230 25
46 COSM145018055 TP53 large intestine,colon,adenoma,NS c.799C>T p.R267* 17:7673704-7673704 25
47 COSM144682265 TP53 large intestine,colon,adenoma,NS c.736G>C p.E246Q 17:7673767-7673767 25
48 COSM123142151 TP53 large intestine,colon,adenoma,NS c.457G>C p.E153Q 17:7673767-7673767 25
49 COSM106075465 TP53 large intestine,colon,adenoma,NS c.733G>C p.G245R 17:7674230-7674230 25
50 COSM121876629 TP53 large intestine,colon,adenoma,NS c.520C>T p.R174* 17:7673704-7673704 25

Copy number variations for Colorectal Cancer from CNVD:

6 (show top 50) (show all 1105)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13323 1 1 124300000 Deletion Colorectal cancer
2 13348 1 1 125000000 Deletion Colorectal cancer
3 13830 1 1 88400000 Loss Colorectal cancer
4 13955 1 101580000 106150000 Loss Colorectal cancer
5 15790 1 11962824 11996159 Copy number MFN2 Colorectal cancer
6 16484 1 125000000 249250621 Gain or loss Colorectal cancer
7 17389 1 142600000 147000000 Loss Colorectal cancer
8 17398 1 142600000 155000000 Loss Colorectal cancer
9 25227 1 185800000 198700000 Gain Colorectal cancer
10 25738 1 193800000 198700000 Gain Colorectal cancer
11 26285 1 198700000 249250621 Gain Colorectal cancer
12 27862 1 214500000 224100000 Loss Colorectal cancer
13 28620 1 224100000 236600000 Gain Colorectal cancer
14 28622 1 224100000 249250621 Gain Colorectal cancer
15 33272 1 44100000 46800000 Copy number MUTYH Colorectal cancer
16 35228 1 61300000 68900000 Loss Colorectal cancer
17 35229 1 61300000 84900000 Loss Colorectal cancer
18 36611 1 78030000 81650000 Loss Colorectal cancer
19 37424 1 91014739 91066075 Copy number NBN Colorectal cancer
20 37518 1 9200000 12700000 Deletion Colorectal cancer
21 37953 1 97315887 98159203 Deletion or duplication DPYD Colorectal cancer
22 38184 10 1 6700000 Deletion KLF6 Colorectal cancer
23 38501 10 103000000 104900000 Deletion CYP17A1 Colorectal cancer
24 39397 10 114699998 114916060 Mutation TCF7L2 Colon cancer
25 41376 10 17300000 18600000 Copy number MRC1 Colorectal cancer
26 42688 10 38000000 40200000 Loss Colorectal cancer
27 42808 10 40300000 135374737 Deletion PTEN Colorectal cancer
28 43829 10 49900000 61200000 Loss Colorectal cancer
29 43980 10 51040559 51454183 Copy number TCF4 Colorectal cancer
30 44156 10 52900000 61200000 Loss Colorectal cancer
31 44276 10 54400000 56790000 Loss Colorectal cancer
32 44881 10 64500000 74900000 Gain Colorectal cancer
33 46118 10 77700000 82000000 Gain Colorectal cancer
34 46544 10 82000000 97000000 Copy number Colorectal cancer
35 46662 10 8380000 10650000 Loss Colorectal cancer
36 47056 10 89500000 92900000 Deletion PTEN Colorectal cancer
37 47132 10 89613174 89718512 Copy number PTEN Colon cancer
38 47730 10 97000000 105800000 Amplification PSD Colorectal cancer
39 48730 11 102100000 102900000 Deletion BIRC2 Colorectal cancer
40 54390 11 43400000 52900000 Gain PTPRJ Colorectal cancer
41 55794 11 55700000 63400000 Loss Colorectal cancer
42 57453 11 63400000 77100000 Gain Colorectal cancer
43 57462 11 63400000 77100000 Amplification CCND1 Colorectal cancer
44 58335 11 67100000 69200000 Amplification CCND1 Colorectal cancer
45 58555 11 68400000 75200000 Gain Colorectal cancer
46 59683 11 77100000 85600000 Deletion THRSP Colorectal cancer
47 61537 12 1 35400000 In KRAS Colorectal cancer
48 61824 12 101600000 133851895 Gain Colorectal cancer
49 63101 12 114300000 125900000 Gain Colorectal cancer
50 63737 12 120700000 133851895 Gain Colorectal cancer

Expression for Colorectal Cancer

LifeMap Discovery
Genes differentially expressed in tissues of Colorectal Cancer patients vs. healthy controls: 35 (show top 50) (show all 57)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 CDH3 cadherin 3 Colon + 6.14 0.000
2 HCAR3 hydroxycarboxylic acid receptor 3 Colon + 5.60 0.000
3 INHBA inhibin subunit beta A Colon + 5.56 0.000
4 CXCL8 C-X-C motif chemokine ligand 8 Colon + 5.26 0.000
5 COL12A1 collagen type XII alpha 1 chain Colon + 4.84 0.000
6 CEMIP cell migration inducing hyaluronidase 1 Colon + 4.63 0.008
7 AQP8 aquaporin 8 Colon - 4.44 0.039
8 GREM1 gremlin 1, DAN family BMP antagonist Colon + 4.37 0.002
9 SST somatostatin Colon - 4.31 0.011
10 FAM3B FAM3 metabolism regulating signaling molecule B Colon + 4.10 0.023
11 PYY peptide YY Colon - 4.03 0.042
12 CXCL5 C-X-C motif chemokine ligand 5 Colon + 3.97 0.004
13 KRT23 keratin 23 Colon + 3.96 0.017
14 MT1M metallothionein 1M Colon - 3.93 0.013
15 BEST4 bestrophin 4 Colon - 3.90 0.021
16 DPEP1 dipeptidase 1 Colon + 3.88 0.039
17 COL11A1 collagen type XI alpha 1 chain Colon + 3.86 0.007
18 TAC1 tachykinin precursor 1 Colon + 3.83 0.031
19 S100A2 S100 calcium binding protein A2 Colon + 3.80 0.013
20 INSL5 insulin like 5 Colon - 3.76 0.048
21 KRT6B keratin 6B Colon + 3.73 0.002
22 MMP3 matrix metallopeptidase 3 Colon + 3.63 0.044
23 CA7 carbonic anhydrase 7 Colon - 3.63 0.024
24 SOX5 SRY-box transcription factor 5 Colon - 3.58 0.001
25 IGL immunoglobulin lambda locus Colon - 3.53 0.020
26 MMP10 matrix metallopeptidase 10 Colon + 3.46 0.023
27 LCN2 lipocalin 2 Colon + 3.42 0.003
28 PIK3CG phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma Colon - 3.42 0.007
29 TTLL5 tubulin tyrosine ligase like 5 Colon - 3.36 0.010
30 VSTM2A V-set and transmembrane domain containing 2A Colon - 3.34 0.022
31 PPP1R10 protein phosphatase 1 regulatory subunit 10 Blood + 3.31 0.000
32 CRNDE colorectal neoplasia differentially expressed Colon + 3.30 0.013
33 CHI3L1 chitinase 3 like 1 Colon + 3.29 0.003
34 CHDH choline dehydrogenase Colon + 3.28 0.012
35 MUC5AC mucin 5AC, oligomeric mucus/gel-forming Colon + 3.28 0.044
36 MTRF1 mitochondrial translation release factor 1 Colon + 3.25 0.006
37 TMCO5B transmembrane and coiled-coil domains 5B (pseudogene) Colon - 3.24 0.008
38 CCDC3 coiled-coil domain containing 3 Colon + 3.22 0.022
39 SPIB Spi-B transcription factor Colon - 3.15 0.025
40 SCGB2A2 secretoglobin family 2A member 2 Colon - 3.15 0.045
41 OR6A2 olfactory receptor family 6 subfamily A member 2 Colon - 3.14 0.001
42 TUBB1 tubulin beta 1 class VI Colon + 3.14 0.002
43 MCM10 minichromosome maintenance 10 replication initiation factor Colon + 3.14 0.001
44 KRT80 keratin 80 Colon + 3.13 0.016
45 DUOX2 dual oxidase 2 Colon + 3.10 0.018
46 IL17F interleukin 17F Colon + 3.10 0.000
47 MMP7 matrix metallopeptidase 7 Colon + 3.09 0.041
48 CFI complement factor I Colon + 3.07 0.027
49 OGN osteoglycin Colon - 3.06 0.022
50 ABCA8 ATP binding cassette subfamily A member 8 Colon - 3.06 0.043
Search GEO for disease gene expression data for Colorectal Cancer.

Pathways for Colorectal Cancer



Pathways directly related to Colorectal Cancer:

# Pathway Source
1 Defective GALNT12 causes CRCS1 Reactome 66
2 Signaling by TCF7L2 mutants Reactome 66
3 Defective MUTYH substrate processing Reactome 66
4 Defective MUTYH substrate binding Reactome 66
5 Defective Base Excision Repair Associated with MUTYH Reactome 66

Pathways related to Colorectal Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 110)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.87 AKT1 APC BRAF CTNNB1 EP300 FGFR3
2
Show member pathways
13.86 AKT1 APC BAX BRAF CHEK2 CTNNB1
3 13.69 AKT1 APC AXIN2 BAX BRAF BUB1
4
Show member pathways
13.6 AKT1 BAX BRAF EP300 FGFR3 NRAS
5
Show member pathways
13.48 TP53 PIK3CA NRAS FGFR3 EP300 CTNNB1
6
Show member pathways
13.42 PIK3CA NRAS FGFR3 EP300 CTNNB1 BRAF
7
Show member pathways
13.13 TP53 NRAS FGFR3 EP300 BRAF AKT1
8
Show member pathways
12.94 PIK3CA NRAS CTNNB1 BRAF AKT1
9
Show member pathways
12.93 EP300 CTNNB1 AXIN2 APC AKT1
10
Show member pathways
12.92 PIK3CA NRAS EP300 BRAF AKT1
11
Show member pathways
12.92 PIK3CA NRAS FGFR3 EP300 BRAF AKT1
12
Show member pathways
12.88 TP53 EP300 CTNNB1 AXIN2 APC
13
Show member pathways
12.88 AKT1 BAX BRAF EP300 NRAS PIK3CA
14
Show member pathways
12.86 PIK3CA NRAS CTNNB1 BRAF AXIN2 APC
15 12.78 PTPRJ PIK3CA NRAS FGFR3 EP300 CTNNB1
16
Show member pathways
12.72 TP53 DCC CTNNB1 BAX APC AKT1
17 12.7 TP53 PIK3CA FGFR3 CTNNB1 BAX APC
18
Show member pathways
12.69 TP53 PIK3CA NRAS FGFR3 AKT1
19
Show member pathways
12.64 TP53 PIK3CA NRAS CTNNB1 BAX AKT1
20
Show member pathways
12.62 PIK3CA NRAS EP300 BRAF BAX
21
Show member pathways
12.52 TP53 PIK3CA NRAS CTNNB1 BRAF AKT1
22
Show member pathways
12.49 TP53 PIK3CA CTNNB1 BRAF BAX AKT1
23 12.48 TP53 CTNNB1 APC AKT1
24
Show member pathways
12.47 AKT1 FGFR3 NRAS PIK3CA
25
Show member pathways
12.46 AKT1 BRAF CTNNB1 PIK3CA
26 12.46 TP53 NRAS FGFR3 BRAF AKT1
27
Show member pathways
12.44 PIK3CA NRAS FGFR3 CTNNB1 BRAF APC
28
Show member pathways
12.42 TP53 BAX AXIN2 AKT1
29
Show member pathways
12.38 TP53 PIK3CA EP300 AKT1
30
Show member pathways
12.38 PIK3CA NRAS CTNNB1 AKT1
31 12.35 AKT1 BRAF CTNNB1 PIK3CA
32
Show member pathways
12.33 PTPRJ PIK3CA BRAF AKT1
33
Show member pathways
12.33 PIK3CA NRAS FGFR3 BRAF
34
Show member pathways
12.32 TP53 PIK3CA BAX AKT1
35
Show member pathways
12.31 TP53 EP300 CHEK2 BUB1
36 12.31 PIK3CA NRAS FGFR3 AKT1
37
Show member pathways
12.27 TP53 EP300 CHEK2 BAX AKT1
38
Show member pathways
12.27 AKT1 BAX CHEK2 CTNNB1 FGFR3 NRAS
39 12.24 TP53 PIK3CA CTNNB1 AKT1
40
Show member pathways
12.22 TP53 NRAS BRAF BAX AKT1
41
Show member pathways
12.22 TP53 PIK3CA NRAS FGFR3 BRAF BAX
42
Show member pathways
12.21 TP53 PIK3CA BAX AKT1
43
Show member pathways
12.19 AKT1 NRAS PIK3CA PTPRJ
44
Show member pathways
12.19 AKT1 CTNNB1 EP300 PIK3CA
45 12.19 PIK3CA NRAS FGFR3 BRAF APC
46
Show member pathways
12.17 TP53 CHEK2 BAX AKT1
47
Show member pathways
12.1 AKT1 BRAF CTNNB1 PIK3CA
48 12.1 TP53 FGFR3 BRAF AXIN2 APC AKT1
49 12.09 NRAS CTNNB1 APC AKT1
50
Show member pathways
12.09 TP53 PIK3CA NRAS